The European patent in question, which has since expired, covered a process for diagnosing the chances of survival for a patient who suffered from acute myeloid leukaemia (AML). It was based on the finding that a certain percentage of patients carrying tandem duplications in a defined portion of the gene encoding a specific receptor tyrosine kinase had a worse prognosis as compared to patients who did not carry this type of mutation. The tandem duplications were easily detectable since they resulted in an elongation of this portion of the gene.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 October 2026 Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.
16 October 2026 All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.
29 September 2026 The gene-editing company has accused a former employee of secretly co-founding a Chinese biotech while still at the company, in a trade secrets lawsuit involving rival base-editing therapies and disputed patent filings.